Similar Papers

Paper Title
Journal
Date
Author
Revolumab: A phase II trial of nivolumab in recurrent IDH-mutant high-grade gliomas.
Caroline Dehais ... Ahmed Idbaih
Journal of Clinical Oncology | VOL. 40
Caroline Dehais, et. al.Caroline Dehais ... Ahmed Idbaih
01 Jun 2022
Salvage Treatment for Recurrent IDH-mutant Diffuse Gliomas after Radiation Therapy
Soumon Rudra ... Jiayi Huang
International Journal of Radiation Oncology*Biology*Physics | VOL. 108
Soumon Rudra, et. al.Soumon Rudra ... Jiayi Huang
09 Sep 2020
Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review
Adomas Bunevicius ... Michael Parsons
Current Oncology Reports | VOL. 22
Adomas Bunevicius, et. al.Adomas Bunevicius ... Michael Parsons
23 Sep 2020
Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI).
Francois Ducray ... Emeline Tabouret
Journal of Clinical Oncology | VOL. 39
Francois Ducray, et. al.Francois Ducray ... Emeline Tabouret
20 May 2021
View more papers

More From: Neuro-oncology practice

Paper Title
Journal
Date
Author
Financial burden after brain tumor diagnosis – the cost of disease for patients and caregivers
Caroline Hertler
Neuro-Oncology Practice | VOL. -
Caroline HertlerCaroline Hertler
20 Jan 2025
‘What is this brain’s story?’ Healthcare professionals’ perspectives of managing brain tumour related personality and behaviour changes
Emma Mcdougall ... Georgia K B Halkett
Neuro-Oncology Practice | VOL. -
Emma Mcdougall, et. al.Emma Mcdougall ... Georgia K B Halkett
17 Jan 2025
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: does time of administration matter?
Marjolein Geurts ...
Neuro-Oncology Practice | VOL. -
Marjolein Geurts, et. al.Marjolein Geurts ...
17 Jan 2025
Should we be testing for germline and “actionable” mutations in all glioma patients?
Jerome J Graber
Neuro-Oncology Practice | VOL. -
Jerome J GraberJerome J Graber
15 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.